Ascendis Pharma Gets Positive European Opinion for Achondroplasia Drug
Ascendis Pharma said it received a positive European regulatory opinion for its once-weekly treatment for children with achondroplasia. The shares closed down 0.6%.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.